Company:  GENOMIC HEALTH INC (GHDX)
Form Type:  10-Q
Filing Date:  5/9/2012 
CIK:  0001131324 
Address:  301 PENOBSCOT DRIVE 
City, State, Zip:  REDWOOD CITY, California 94063 
Telephone:  650-556-9300 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$26.46  
Change: 
-0.30 (-1.12%)  
Trade Time: 
Apr 24  
Market Cap: 
$825.13M
Description of Business
This report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this report, the words "expects," "anticipates," "intends," "estimates," "plans," "believes," and similar expressions are intended to identify forward-looking statements. These are statements that relate to future periods and include statements about our expectation that, for the foreseeable future, a significant amount of our revenues will be derived from Oncotype DX for invasive breast cancer; the factors that may impact our financial results; our ability to achieve sustained profitability; our business strategy and our ability to achieve our strategic goals; our expectations regarding product revenues and the sources of those revenues; the amount of future revenues that we may derive from Medicare patients or categories of patients; our belief that we may become more dependent on Medicare reimbursement in the future; our plans to pu
Register for EDGAR Pro and access this filing in:     
  FORM 10-Q
    PART 1: FINANCIAL INFORMATION
      Item 1. Financial Statements
        BALANCE SHEET
        INCOME STATEMENT
        CASH FLOW
        NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
      ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL ...
      ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT ...
      ITEM 4. CONTROLS AND PROCEDURES.
    PART II. OTHER INFORMATION
      ITEM 1A. RISK FACTORS.
      ITEM 6. EXHIBITS
    SIGNATURES
    EXHIBIT INDEX
  EXHIBIT 31.1
    Certification of the Chief Executive Officer Pursuant to ...
  EXHIBIT 31.2
    Certification of the Chief Financial Officer Pursuant to ...
  EXHIBIT 32.1
  EXHIBIT 32.2
BROKERAGE PARTNERS